GlassScriptPhysician profile
Paul S Hoffman
NPI 1144249509
$1,340.86
in general payments reported to CMS, 2019-2025
24 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $179 · 2022: $309 · 2023: $150 · 2024: $552 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462.28 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $114.57 | 2022-2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $98.53 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $92.95 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.15 | 2022-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $55.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.62 | 2024 | |
| Glaxosmithkline, LLC. | $44.15 | 2021 | |
| Exact Sciences Corporation | $38.92 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $31.21 | 2022 | |
| Hologic Sales and Service, LLC | $27.63 | 2024 | Aptima, Thinprep 2000 Processor |
| Neurocrine Biosciences, INC. | $27.43 | 2022 | |
| Biomarin Pharmaceutical INC. | $26.08 | 2024 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $25.60 | 2024 | Crysvita |
| Boston Scientific Corporation | $23.96 | 2025 | Watchman Access System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.32 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $22.16 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $20.15 | 2022 | |
| Acadia Pharmaceuticals INC | $19.52 | 2022 | |
| Phadia US INC. | $16.42 | 2024 | Immunocap |
| Nestle Healthcare Nutrition INC. | $16.04 | 2021 | |
| Currax Pharmaceuticals LLC | $14.72 | 2025 | Contrave |
| Xeris Pharmaceuticals, INC. | $14.57 | 2021 | |
| Eisai INC. | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.